Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renovorx Inc (NQ: RNXT )

1.020 +0.022 (+2.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Renovorx Inc

< Previous 1 2 3 Next >
RenovoRx CEO Issues Update Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From RenovoRx , Inc.
Via Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces $11.1 Million at Market Private Placement
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
From RenovoRx, Inc.
Via Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Via Get News
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Via TheNewswire.com
RenovoRx, Inc. Stock Presents A Compelling Value Proposition After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
Via AB Newswire
Topics Death
Exposures Death
RenovoRx, Inc. Stock Surges After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
Via AB Newswire
Topics Death
Exposures Death
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an... 
Via TheNewswire.com
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.